Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Eli Lilly and Company
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
A Clinical Study in Patients with Small Cell Lung Cancer
Phase 1b Determine a safe and tolerable Phase 2 dose of LY2940680 in combination with carboplatin and etoposide followed by LY2940680 in patients with extensive-stage SCLC. Phase 2 Progression-f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 4 ans
A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer
Compare the antitumor activity in first-line therapy of paclitaxel- and carboplatin-combination therapy plus enzastaurin followed by enzastaurin maintenance therapy (Regimen A), versus paclitaxel- and...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 4 ans
A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of the study is to compare the efficacy of 2 different switching approaches; at the end of the fast (Week 2) and slow (Week 10) transition from stimulants to atomoxetine as measu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 4 ans
A Randomized, Double-Blind, PLacebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhibitors
- To evaluate the efficacy of tadalafil 5 mg (with possible down-titration to 2.5 mg) compared with placebo, when taken orally once a day over 12 weeks, in improving erectile function in men with ED w...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 4 ans
An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with Relapsed Diffuse Large B-Cell Lymphoma
Main objective : evaluation of progression free survival on R-GEMOX and enzastaurin, 1 year after treatment start, in patients with relapsed DLBCL or transformed (CD20+) indolent lymphoma, who are ol...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
A 1-year study to compare long-acting insulin therapies in patients with type 2 diabetes
The primary objective is to demonstrate that LY2605541 is noninferior to insulin glargine for the change in HbA1c from baseline to 26 weeks of treatment in patients with T2DM treated with basal insuli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
Protocol F1D-MC-HGKR. Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder
The primary objective of this study is to assess the superiority of olanzapine (up to 30 mg/day) plus carbamazepine (400 to 1200 mg/day) versus placebo plus carbamazepine (400 to 1200 mg/day) in impro...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment with LY2216684 in Adult Patients with Major Depressive Disorder
To assess whether LY2216684 is superior to placebo in the treatment of patients with MDD, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision® (DSM-I...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
Prasugrel in comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE) - TIMI 44
-To compare the inhibition of platelet aggregation (IPA) to 20 µM adenosine diphosphate (ADP) measured at 6 hours (±30 minutes) after prasugrel 60 mg loading dose (LD) versus clopidogrel 600 mg LD in ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
A study in T-ALL/T-LBL Patients
Phase1: to determine the recommended dose of LY3039478 in combination with dexamethasone in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
13
14
15
16
17
18
19
20
21
22
Suivant